Otsuka/Lundbeck’s Rexulti PTSD Claim Will Test US FDA AdComm’s Supportive Evidence Flexibility

 
• By Bridget Silverman
  
An FDA advisory committee will test Otsuka/Lundbeck's use of a Phase II trial as supportive data in PTSD after a Phase III trial failed. (Shutterstock)

More from US Advisory Committees

More from Product Reviews